Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Circulation

• Publication date

  1984-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.69.6.1161PMID 6546902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina

  1984cited by this paper
• Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.

  1983cited by this paper
• Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

  1983cited by this paper
• Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells.

  1982cited by this paper
• Urinary excretion of prostaglandin E2, prostaglandin F2 alpha, and thromboxane B2 in normotensive and hypertensive subjects on varying sodium intakes.

  1982cited by this paper
• Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.

  1982cited by this paper
• Blood Flow Reductions in Stenosed Canine Coronary Arteries: Vasospasm or Platelet Aggregation?

  1982cited by this paper
• Clinicopathologic correlates of acute ischemic heart disease syndromes.

  1981cited by this paper
• Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.

  1981cited by this paper
• Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase.

  1981cited by this paper
• Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.

  1981cited by this paper
• Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle

  1981cited by this paper
• Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

  1981cited by this paper
• Thromboxane A2 in Vasotonic Angina Pectoris

  1981cited by this paper
• Prostaglandins and ischemic heart disease.

  1981cited by this paper
• Significance of Regional Wall Thickening Abnormalities Relative to Transmural Myocardial Perfusion in Anesthetized Dogs

  1980cited by this paper
• The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog.

  1980cited by this paper
• Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

  1980cited by this paper
• Effects of prostaglandins and thromboxane A2 on the coronary circulation of adult dogs and puppies.

  1980cited by this paper
• Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation.

  1979cited by this paper
• Platelet and blood vessel arachidonate metabolism and interactions.

  1979cited by this paper
• Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

  1979cited by this paper
• Comparison of coronary arteriograms with direct measurements of stenosed coronary arteries in dogs.

  1978cited by this paper
• Synchronized pulsed Doppler blood flow and ultrasonic dimension measurement in conscious dogs.

  1978cited by this paper
• Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

  1978cited by this paper
• Blood flow measurements with radionuclide-labeled particles.

  1977cited by this paper
• Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin

  1976cited by this paper
• An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

  1976cited by this paper
• Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma.

  1975cited by this paper
• Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

  1975cited by this paper
• Radioimmunoassay of Prostaglandins Fα, E1 and E2 in Human Plasma

  1975cited by this paper

• Insights from Autopsy-initiated Pathological Studies of the Pathogenesis and Clinical Manifestations of Atherosclerosis and Ischemic Heart Disease: Part II. Ischemic Heart Disease.

  2025cites this paper
• Pathobiology of myocardial and cardiomyocyte injury in ischemic heart disease: Perspective from seventy years of cell injury research.

  2024cites this paper
• United States Patent ( 10 ) Patent No . : US 7 , 618 , 949 B 2

  2017cites this paper
• Pathobiology of Cardiovascular Diseases: Past, Present and Future Perspectives (CVP 25th Anniversary Special Review Article) Pathobiology of Ischemic Heart Disease: Past, Present and Future

  2016cites this paper
• Pathobiology of Ischemic Heart Disease: Past, Present and Future.

  2016cites this paper
• Coronary Heart Disease Syndromes: Pathophysiology and Clinical Recognition

  2015cites this paper
• Anti-platelet Effects of Dimethyl Sulfoxide via Down-regulation of COX-1 and TXA₂ Synthase Activity in Rat Platelets

  2014cites this paper
• von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina

  2013cites this paper
• James Willerson: Leading the Texans' Fight Against Heart Disease

  2012cites this paper
• James Willerson: leading the Texans' fight against heart disease. Interview by Ruth Williams.

  2012cites this paper
• In vivo models for the evaluation of antithrombotics and thrombolytics.

  2010cites this paper
• Coronary cyclic flow variations following primary angioplasty is associated with poor short-term prognosis.

  2008cites this paper
• DP Prostanoid Receptor

  2008cites this paper
• The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia

  2005cites this paper
• Kawai Pathogenesis of Acute Myocardial Infarction 1035 Regulatory System of Bioactive Substances in the Vessel Wall in Evolving Myocardial Infarction

  2005cites this paper
• MYOCARDIAL ISCHEMIA Cooperative mediation by serotonin S 2 and thromboxane A 2 / prostaglandin H 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses

  2005cites this paper
• coronary arteries . von Willebrand ' s disease prevents occlusive thrombosis in stenosed and injured porcine

  2005cites this paper
• Formation in Primates With Monoclonal Antibodies

  2005cites this paper
• Evolving Concepts

  2005cites this paper
• Endothelium-Injured Canine Coronary Arteries

  2005cites this paper
• Ischemic Syndromes

  2005cites this paper
• Unstable Coronary Syndromes

  2005cites this paper
• Effect of complement depletion on O2 supply and consumption in ischemic dog myocardium

  2005cites this paper
• Thromboxane A2 and Serotonin are Possible Mediators

  2005cites this paper
• Drugs for the prevention of coronary thrombosis: From an animal model to clinical trials

  2004cites this paper
• Evolution of Cardiac Markers in Clinical Trials

  2003cites this paper
• Serotonin S, and Thromboxane A,-Prostaglandin H, Receptor Blockade Provide Protection Against Epinephrine-Induced Cyclic Flow Variations in Severely Narrowed Canine Coronary Arteries

  2003cites this paper
• Folts Cyclic Flow Animal Model for Studying in Vivo Platelet Activity and Platelet Interactions with Damaged Arterial Walls

  2001cites this paper
• Thrombi in Acute Coronary Syndromes

  2000cites this paper
• Thrombi in Acute Coronary Syndromes Revisited and Revised

  2000cites this paper
• Thrombi in acute coronary syndromes : revisited and revised.

  2000cites this paper
• Impact of delayed reperfusion of myocardial hibernation on myocardial ultrastructure and function and their recoveries after reperfusion in a pig model of myocardial hibernation.

  2000cites this paper
• Interaction Between Endothelial P-Selectin and Leukocyte Sialyl LewisX Endothelial Injuries of Coronary Arteries Distal to Thrombotic Sites : Role of Adhesive

  1999cites this paper
• Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.

  1999cites this paper
• Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P-selectin and leukocyte sialyl LewisX.

  1999cites this paper
• In Vivo Models of Thrombosis

  1999cites this paper
• Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation.

  1998cites this paper
• The role of myocardial revascularization preceding noncardiac surgery.

  1998cites this paper
• A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.

  1998cites this paper
• James Thornton Willerson, MD: A Conversation With the Editor1

  1997cites this paper
• Experimental Evidence for Enhancement of Thrombolysis by Conventional Thrombolytic Drugs

  1997cites this paper
• James Thornton Willerson, MD: a conversation with the editor. Interview by William Clifford Roberts.

  1997cites this paper
• A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent.

  1997cites this paper
• Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem.

  1996cites this paper
• Mechanisms contributing to the abrupt conversion from stable to unstable angina and myocardial infarction

  1996cites this paper
• Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin

  1996cites this paper
• Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody.

  1996cites this paper
• Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries.

  1996cites this paper
• The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis.

  1996cites this paper
• Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries.

  1996cites this paper
• Inhibition of thromboxane A2 activity during warm ischemia of the liver.

  1996cites this paper
• Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically?

  1996cites this paper
• Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.

  1995cites this paper
• Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease.

  1995cites this paper
• Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries.

  1995cites this paper
• Effects of gallopamil on epinephrine and norepinephrine plasmatic levels and on TxB2 and beta-tg release in patients with coronary artery disease during adrenergic stimulus with cold pressor test.

  1995cites this paper
• Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries.

  1995cites this paper
• Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products.

  1995cites this paper
• Platelet, endothelium and smooth muscle cell-derived mediators contributing to the development of unstable angina and myocardial infarction

  1995cites this paper
• Gene therapy to restore prostacyclin presence to injured endothelium.

  1995cites this paper
• Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall.

  1994cites this paper
• Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.

  1994cites this paper
• Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

  1994cites this paper
• The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.

  1994cites this paper
• Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody.

  1994cites this paper
• Effects of ketanserin on epicardial coronary arteries after coronary angioplasty in patients with stable angina.

  1994cites this paper
• Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.

  1994cites this paper
• Antiplatelet and antithrombin therapy.

  1994cites this paper
• Abolition of Cyclic Flow Variations in Stenosed, Endothelium‐Injured Coronary Arteries in Nonhuman Primates With a Peptide Fragment (VCL) Derived From Human Plasma von Willebrand Factor–Glycoprotein Ib Binding Domain

  1994cites this paper
• Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs.

  1993cites this paper
• Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans.

  1993cites this paper
• Monitoring cyclical coronary blood flow alterations after coronary angioplasty for stent restenosis with a Doppler guide wire.

  1993cites this paper
• Serotonin: From Cell Biology to Pharmacology and Therapeutics

  1993cites this paper
• Platelets, Platelet Mediators, and Unstable Coronary Artery Disease Syndromes

  1993cites this paper
• Inhibition by the Combined Ca2+ and 5‐HT2 Receptor Antagonist Nexopamil (LU 49938) of Intracoronary Thrombus Formation in a Canine Model of Arterial Stenosis and Intimal Damage

  1993cites this paper
• Quantitative changes of hydroxyacid formation during platelet-neutrophil interaction.

  1993cites this paper
• Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries.

  1993cites this paper
• Interplay Between Platelet‐Derived 5‐Hydroxytryptamine and Arachidonic Acid Metabolites Limits the Thrombolytic Efficacy of Streptokinase Against Canine Platelet‐Rich Coronary Thrombosis

  1993cites this paper
• Combined ADP and Thromboxane A2 Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium‐Injured Arteries in Nonhuman Primates

  1993cites this paper
• Cyclic flow alterations and neointimal proliferation following experimental coronary stenosis and endothelial injury

  1993cites this paper
• The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction.

  1993cites this paper
• The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.

  1993cites this paper
• ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.

  1992cites this paper
• Coronary Cyclic Flow Variations “Precondition” Ischemic Myocardium

  1992cites this paper
• Should all patients with risk factors for ischemic heart disease receive aspirin?

  1992cites this paper
• Specific Platelet Mediators and the Abrupt Progression of Coronary Artery Stenoses

  1992cites this paper
• Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation.

  1992cites this paper
• Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis.

  1992cites this paper
• Endogenous Nitric Oxide Protects Against Platelet Aggregation and Cyclic Flow Variations in Stenosed and Endothelium‐Injured Arteries

  1992cites this paper
• Experimental Carotid Stenosis and Endothelial Injury in the Rabbit: An In Vivo Model to Study Intravascular Platelet Aggregation

  1992cites this paper
• Effects of serotonin and thromboxane A2 on the coronary collateral circulation.

  1992cites this paper
• The use of aspirin in ischemic heart disease.

  1992cites this paper
• Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries

  1992cites this paper
• Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.

  1991cites this paper
• Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.

  1991cites this paper
• Pathophysiology of acute coronary syndromes.

  1991cites this paper
• [Thromboxane antagonism in thrombocytes--pathophysiology, pharmacology and possible clinical significance].

  1991cites this paper
• Inhibition of platelet function in vivo or in vitro by organic nitrates.

  1991cites this paper
• Documentation of experimentally induced thrombus formation using intravascular ultrasound.

  1991cites this paper
• Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor.

  1991cites this paper